Top of page

Student/Staff Portal
Global Site Navigation

School of Medical and Health Sciences

Local Section Navigation
You are here: Main Content

Related Contents

Ms Anna Reid

Clinical Study Coordinator

Staff Member Details
Telephone: +61 8 6304 2803
Email: anna.reid@ecu.edu.au
Campus: Joondalup  
ORCID iD: https://orcid.org/0000-0002-4588-1679

Anna is a Research Assistant in the cancer research program in the Centre for Precision Health

Qualifications

  • Bachelor of Science in Biomedical Sciences, Murdoch University, 2008.

Research Outputs

2024

Journal Articles

  • Abed, A., Reid, A., Law, N., Millward, M., Gray, E. (2024). HLA-A01 and HLA-B27 Supertypes, but Not HLA Homozygocity, Correlate with Clinical Outcome among Patients with Non-Small Cell Lung Cancer Treated with Pembrolizumab in Combination with Chemotherapy. Cancers, 16(17), Article number 3102. https://doi.org/10.3390/cancers16173102.

2023

Journal Articles

  • Beasley, A., De Bruyn, D., Beasley, L., Al-Ogaili, Z., Isaacs, T., Bentel, J., Reid, A., Dwarkasing, R., Pereira, M., Khattak, A., Meniawy, T., Millward, M., Brosens, E., De Klein, A., Chen, F., Kiliҫ, E., Gray, E. (2023). Detection of metastases using circulating tumour DNA in uveal melanoma. Journal of Cancer Research and Clinical Oncology, 2023(Article in press), 11 pages. https://doi.org/10.1007/s00432-023-05271-3.
  • Warburton, L., Reid, A., Amanuel, B., Beasley, L., Millward, M., Gray, E. (2023). Detectable ctDNA at the time of treatment cessation of ipilimumab and nivolumab for toxicity predicts disease progression in advanced melanoma patients. Frontiers in Oncology, 13(Article in press), Article number 1280730. https://doi.org/10.3389/fonc.2023.1280730.
  • Abed, A., Beasley, A., Reid, A., Law, N., Beasley, L., Millward, M., Lo, J., Gray, E. (2023). Circulating pre-treatment T-cell receptor repertoire as a predictive biomarker in advanced or metastatic non-small-cell lung cancer patients treated with pembrolizumab alone or in combination with chemotherapy. ESMO Open, 8(6), Article number 102066. https://doi.org/10.1016/j.esmoop.2023.102066.
  • Calapre, L., Giardina, T., Beasley, A., Reid, A., Stewart, C., Amanuel, B., Meniawy, T., Gray, E. (2023). Identiication of TP53 mutations in circulating tumour DNA in high grade serous ovarian carcinoma using next generation sequencing technologies. Scientific Reports, 13(1), Article number 278. https://doi.org/10.1038/s41598-023-27445-2.

2022

Journal Articles

  • Marsavela, G., McEvoy, A., Pereira, M., Reid, A., Al-Ogaili, Z., Warburton, L., Khattak, A., Abed, A., Meniawy, T., Millward, M., Ziman, M., Beasley, L., Gray, E. (2022). Detection of clinical progression through plasma ctDNA in metastatic melanoma patients: a comparison to radiological progression. British Journal of Cancer, 126(3), 401-408. https://doi.org/10.1038/s41416-021-01507-6.

2021

Book Chapters

  • Marsavela, G., Reid, A., Gray, E., Beasley, L. (2021). Isolation and quantification of plasma circulating tumor DNA from melanoma patients. Melanoma. Methods and Protocols (247-263). Humana Press. https://doi.org/10.1007/978-1-0716-1205-7_19.

Journal Articles

  • Beasley, A., Isaacs, T., Vermeulen, T., Freeman, J., Desousa, J., Bhikoo, R., Hennessy, D., Reid, A., Chen, F., Bentel, J., McKay, D., Conway, R., Pereira, M., Mirzai, B., Beasley, L., Erber, W., Ziman, M., Gray, E. (2021). Analysis of Circulating Tumour Cells in Early-Stage Uveal Melanoma: Evaluation of Tumour Marker Expression to Increase Capture. Cancers, 13(23), Article 5990. https://doi.org/10.3390/cancers13235990.

2020

Journal Articles

  • Warburton, L., Beasley, L., Pereira, M., Reid, A., Robinson, C., Amanuel, B., Ziman, M., Millward, M., Gray, E. (2020). Circulating Tumour DNA in Advanced Melanoma Patients Ceasing PD1 Inhibition in the Absence of Disease Progression. Cancers, 12(11), Article number 3486. https://doi.org/10.3390/cancers12113486.
  • Marsavela, G., Lee, J., Beasley, L., Wong, S., Pereira, M., McEvoy, A., Reid, A., Robinson, C., Warburton, L., Abed, A., Khattak, A., Meniawy, T., Dawson, S., Sandhu, S., Carlino, M., Menzies, A., Scolyer, R., Long, G., Amanuel, B., Millward, M., Ziman, M., Rizos, H., Gray, E. (2020). Circulating Tumor DNA Predicts Outcome from First-, but not Second-line Treatment and Identifies Melanoma Patients Who May Benefit from Combination Immunotherapy. Clinical Cancer Research, 26(22), 5926-5933. https://doi.org/10.1158/1078-0432.CCR-20-2251.
  • Marsavela, G., Johansson, P., Pereira, M., McEvoy, A., Reid, A., Robinson, C., Warburton, L., Khattak, A., Meniawy, T., Amanuel, B., Millward, M., Hayward, N., Ziman, M., Gray, E., Beasley, L. (2020). The Prognostic Impact of Circulating Tumour DNA in Melanoma Patients Treated with Systemic Therapies-Beyond BRAF Mutant Detection. Cancers, 12(12), Article number 3793. https://doi.org/10.3390/cancers12123793.
  • Khattak, A., Abed, A., Reid, A., McEvoy, A., Millward, M., Ziman, M., Gray, E. (2020). Role of Serum Vascular Endothelial Growth Factor (VEGF) as a Potential Biomarker of Response to Immune Checkpoint Inhibitor Therapy in Advanced Melanoma: Results of a Pilot Study. Frontiers in Oncology, 10(30 June 2020), Article number 1041. https://doi.org/10.3389/fonc.2020.01041.
  • Khattak, A., Reid, A., Freeman, J., Pereira, M., McEvoy, A., Lo, J., Frank, M., Meniawy, T., Didan, A., Spencer, I., Amanuel, B., Millward, M., Ziman, M., Gray, E. (2020). PD-L1 Expression on Circulating Tumor Cells May Be Predictive of Response to Pembrolizumab in Advanced Melanoma: Results from a Pilot Study. The Oncologist, 25(3), e520-e527. https://doi.org/10.1634/theoncologist.2019-0557.

2019

Journal Articles

  • Beasley, L., Giardina, T., Robinson, C., Reid, A., Al-Ogaili, Z., Pereira, M., McEvoy, A., Warburton, L., Hayward, N., Khattak, A., Meniawy, T., Millward, M., Amanuel, B., Ziman, M., Gray, E. (2019). Locus-specific concordance of genomic alterations between tissue and plasma circulating tumor DNA in metastatic melanoma. Molecular Oncology, 13(2), 171-184. https://doi.org/10.1002/1878-0261.12391.
  • Aya-Bonilla, C., Gray, E., Manikandan, J., Freeman, J., Zaenker, P., Reid, A., Khattak, M., Frank, M., Millward, M., Ziman, M. (2019). Immunomagnetic-Enriched Subpopulations of Melanoma Circulating Tumour Cells (CTCs) Exhibit Distinct Transcriptome Profiles. Cancers, 11(2), Article number 157. https://doi.org/10.3390/cancers11020157.
  • Osborne, D., Domenico, J., Luo, Y., Reid, A., Amato, C., Zhai, Z., Gao, D., Ziman, M., Dinarello, C., Robinson, W., Fujita, M. (2019). Interleukin‐37 is highly expressed in regulatory T cells of melanoma patients and enhanced by melanoma cell secretome. Molecular Carcinogenesis, 58(9), 1670-1679. https://doi.org/10.1002/mc.23044.
  • McEvoy, A., Pereira, M., Reid, A., Pearce, R., Cowell, L., Al-Ogaili, Z., Khattak, A., Millward, M., Meniawy, T., Gray, E., Ziman, M. (2019). Monitoring melanoma recurrence with circulating tumor DNA: a proof of concept from three case studies. Oncotarget, 10(2), 113-122. https://doi.org/10.18632/oncotarget.26451.

2018

Journal Articles

  • Dunkel, Y., Reid, A., Ear, J., Aznar, N., Millward, M., Gray, E., Pearce, R., Ziman, M., Ghosh, P. (2018). Prognostic relevance of CCDC88C (Daple) transcripts in the peripheral blood of patients with cutaneous melanoma. Scientific Reports, 8(1), Article number 18036. https://doi.org/10.1038/s41598-018-36173-x.

2015

Journal Articles

  • Reid, A., Freeman, J., Millward, M., Ziman, M., Gray, E. (2015). Detection of BRAF-V600E and V600K in melanoma circulating tumour cells by droplet digital PCR. Clinical Biochemistry, 48(15), 999-1002. https://doi.org/10.1016/j.clinbiochem.2014.12.007.
  • Gray, E., Reid, A., Bowyer, S., Beasley, L., Siew, K., Pearce, R., Cowell, L., Frank, M., Millward, M., Ziman, M. (2015). Circulating Melanoma Cell Subpopulations: Their Heterogeneity and Differential Responses to Treatment. Journal of Investigative Dermatology, 135(8), 2040-2048. https://doi.org/10.1038/jid.2015.127.
  • Gray, E., Rizos, H., Reid, A., Boyd, S., Pereira, M., Lo, J., Tembe, V., Freeman, J., Lee, J., Scolyer, R., Siew, K., Lomma, C., Cooper, A., Khattak, M., Meniawy, T., Long, G., Carlino, M., Millward, M., Ziman, M. (2015). Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma. Oncotarget, 6(39), 42008-42018. https://doi.org/10.18632/oncotarget.5788.

2014

Journal Articles

  • Klinac, D., Gray, E., Freeman, J., Reid, A., Bowyer, S., Millward, M., Ziman, M. (2014). Monitoring changes in circulating tumour cells as a prognostic indicator of overall survival and treatment response in patients with metastatic melanoma. BMC Cancer, 14(1), Article number 423. https://doi.org/10.1186/1471-2407-14-423.

2013

Journal Articles

  • Reid, A., Millward, M., Pearce, R., Lee, M., Frank, M., Ireland, A., Monshizadeh, L., Rai, T., Heenan, P., Medic, S., Kumarasinghe, P., Ziman, M. (2013). Markers of circulating tumour cells in the peripheral blood of patients with melanoma correlate with disease recurrence and progression. British Journal of Dermatology, 168(1), 85-92. https://doi.org/10.1111/bjd.12057.

Research Projects

  • Multimodal Liquid biopsy to Predict Response of Melanoma to Immuno-Oncology, Spinnaker Health Research Foundation, Janine Chalwell Gift Grant, 2022 ‑ 2024, $102,459.
  • Predictive significance of circulating tumour cells (CTCs), circulating tumour DNA (ctDNA) and serum vascular endothelial growth factor (VEGF) in advanced melanoma patients treated with pembrolizumab, Merck Sharp and Dohme (Australia) Pty Ltd, Grant, 2016 ‑ 2019, $73,300.
  • Neon Transfection System and Biomedical Research Grade -30oC Freezer for Alzheimer’s and Melanoma Research, National Health and Medical Research Council, Equipment Grant 2011, 2011 ‑ 2012, $10,927.
Skip to top of page